Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. He describes the options available for prophylaxis and how he treats the toxicities that do arise.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Oncology News Central Peer-Spectives
“Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care
New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target”
Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic
Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care
Get summaries like this every morning.
Free AI-powered recaps of Oncology News Central Peer-Spectives and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.